🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Bob Kyle described monoclonal gammopathy of undetermined significance (MGUS) in 1978. He wrote an update with 40 years follow up in NEJM in 2018. Legend. ~5% of people age 50+ have MGUS. The main risk with MGUS is progression to myeloma at a rate of 1% per year. #MedTwitter

Thrilled to share the first pre-print from our lab! We tackled a big question: Why are some pediatric leukemias extremely aggressive? We explored the developmental origins of fusion-driven acute myeloid leukemia (AML). Let's dive in! #AML #NUP98 n/13

Spatial multi-omics reveals cell-type-specific nuclear compartments nature Cai Lab Yodai Takei nature.com/articles/s4158…

Must read 👇

How to prevent or treat progression of myeloproliferative neoplasms to the accelerated phase or blast phase? Read the new review by Patel and Rampal. haematologica.org/article/view/h…

Excellent work to my fellow Brian Grainger and Phil Thompson on this review just out in Blood Journal Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia. ashpublications.org/blood/article-…

Distinct routes of clonal progression in #SF3B1-mutant myelodysplastic syndromes doi.org/10.1182/blooda… #MDSsm #RUNX1 #STAG2 Blood Advances MDS Foundation AA&MDSIF International Consortium for MDS (icMDS) MDS Hub

Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes nature.com/articles/s4146… #MDSsm Nature Communications MDS Foundation AA&MDSIF International Consortium for MDS (icMDS) MDS Hub #CCUS

Read the new review on the general diagnosis, complications, and management of myeloproliferative neoplasms, including a focus on interferon-α therapy as a potential, early disease-modifying drug. haematologica.org/article/view/h…

📝 A new study published in Blood Cancer Journal found significantly reduced 8-week mortality with 7-day venetoclax vs standard exposure (6% vs 16%), in patients with newly diagnosed AML. More news: aml-hub.com #AMLsm #MedNews #MedEd

Of the 12 patients who reversed from MRD negative to MRD positive and restarted maintenance, 4 progressed and all remained alive. ow.ly/7kkM50VTAg9 #lymphoidneoplasia #multiplemyeloma

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine nejm.org/doi/full/10.10… With use of potent BCR::ABL1 directed TKI, long term survival outcome has significantly improved (>75%). Important question from clinical standpoint : Is

The remarkable story of Velcade. In the year 2000, a few of us attended an angiogenesis meeting in Boston. We were there to discuss thalidomide But a side meeting that evening led to trial that went on to get Velcade FDA approved for myeloma. NEJM Story in thread.

The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. Plasma Cell Pete Noopur Raje Tom Martin Yi Lin Deepu Madduri

Clonal hematopoiesis is a phenomenon typically associated with aging, whereby single HSC clones bearing a set of hallmark somatic mutations are dramatically overrepresented compared with their nonmutant counterparts. ow.ly/mych50VXjUF #transfusionmedicine

Recent studies suggest that therapy resistance correlates with distinct acute myeloid leukemia subsets and that the differentiation status of leukemia cells affects sensitivity to BCL-2 inhibition. ow.ly/OVYy50VXkPq #myeloidneoplasia

The immunotherapeutic revolution in the treatment of B-cell hematologic malignancies has been a remarkable achievement in the annals of modern medicine. ow.ly/8XaT50VXkgq #clinicaltrialsandobservations

New Recommendations on Platelet Transfusions Updated guidelines from the Association for the Advancement of Blood & Biotherapies strongly recommend lowering platelet transfusion thresholds even further. jwat.ch/3ZBvRvF #guidelines #MedTwitter

Patients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity. ow.ly/tEXM50W7tLk #myeloidneoplasia #transplantation #clinicaltrialsandobservations

Thrilled to present 2 x posters on FXai related GI bleeding on behalf of the AXIOM UK investigators! #ISTH2025